2023年第114届美国癌症研究协会年会(AACR)将于4月14日至19日在奥兰多举行，AACR年会是世界上规模最大的癌症研究会议之一，每年都会吸引来自世界各地的近20000名专业人士出席会议。与会者包括科学家、临床医生、其他医疗专业人员、患者等，分享癌症和相关生物医学科学的最新进展，通过研究、教育、交流、协作，预防和治疗癌症。

今天该会议公布了最新口头报告摘要题目等内容，世易小编已整理好，供您参考。

关注“世易医健”微信公众号，我们会及时报道AACR 2023最具亮点的精华内容，以飨读者。

Collaboration between tumor cells and the inflammatory environment of distant organ drives metastasis by impairing effector immune cell deployment

• 宋尔卫 院士，中山大学孙逸仙纪念医院

Activation of antitumor immunity by bacteria-derived signals: Pyroptosis and beyond

• 邵峰 院士，北京生命科学研究所

CT003 - IMbrave050: Phase 3 study of adjuvant atezolizumab + bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation

• Pierce Chow，National Cancer Centre Singapore

• 秦叔逵教授，南京金陵医院

CT008 - Pembrolizumab (pembro) in combination with gemcitabine and cisplatin (gem/cis) for advanced biliary tract cancer (BTC): Phase 3 KEYNOTE-966 study

• Robin Kate Kelley, University of California San Francisco

• 任正刚教授，复旦大学附属中山医院

CT030 - Phase I study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors: Updated results of the phase I study

• 周清教授，广东省人民医院

CT031 - A first-in-human, phase 1a/1b, open-label, dose-escalation and expansion study to investigate the safety, pharmacokinetics, and antitumor activity of the RAF dimer inhibitor BGB-3245 in patients with advanced or refractory tumors

•  Alison M. Schram, 美国纪念斯隆-凯特琳癌症中心

•  Lusong Luo，百济神州

CT037 - Nivolumab plus ipilimumab vs chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma: CheckMate 649 biomarker analyses

• Yelena Y. Janjigian, 美国纪念斯隆-凯特琳癌症中心

• 沈琳教授，北京大学肿瘤医院

• 刘天舒教授，复旦大学附属中山医院

NG10 - Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets

• Xu Duo，南京医科大学第一附属医院

Translating fragmentomics discoveries into impacts in liquid biopsies

• Dennis Lo. 中国香港中文大学

1130 - A phase 1 dose escalation study of GCC19CART - a novel CoupledCAR therapy for subjects with metastatic colorectal cancer

• 肖磊，斯丹赛生物技术CEO 

1137 - Identification of a high selective SMARCA2 degrader which effectively suppresses the SMARCA4-deficient tumors in vitro and in vivo

• 唐任宏，先声药业

1145-PH020-803: an MTA-cooperative and brain-penetrable PRMT5 inhibitor that selectively targets MTAP-deleted tumors

• Feng Gao, Puhe Biopharma

1194-Evolution of immune and stromal cell states during the gastric cancer continuum

• Ruiping Wang, 美国MD Anderson癌症中心

• 程向东教授，中国科学院大学附属肿瘤医院（浙江省肿瘤医院）

3427 - ICP-490 is a highly potent and selective IKZF1/3 degrader with robust anti-tumor activities against multiple myeloma and non-Hodgkin’s lymphoma

• 欧阳雪松，诺诚健华

3448 - Discovery of HYP-2A,a 2nd- generation KRASG12C inhibitor exhibits potent in vivo efficacy in drug resistant tumor models

• 陈寿军，汇宇药业

3450 - Discovery and preclinical study of novel BTK degrader HZ-Q1070

• 刘兴国，和正医药

3451 - XS-04: A first-in-class dual IRAK4/BTK inhibitor for the treatment of hematological malignancies

• Chunyan Zhao, Jianfei Wang, Aiguo Liu, Xin Gao, Yanfen Teng, Lei Liu, Yang Zhang, Xiaohong Yu. XSXH Therapeutics Co., Ltd, 药明康德

3474 - Identification of the selective CBL-b inhibitors which effectively prevent T cells from exhaustion and demonstrate synergistic anti-tumor activity in combination with an anti-PD1 antibody

• 唐任宏，先声药业

5738 - A pan-ras mRNA vaccine elicits specific immune responses and inhibits tumor growth in the mouse model of colon cancer

• 沈栋博士，RNAimmune/圣诺医药

LB021 / 13 - KN-052, a novel PDL1/OX40 bispecific antibody, exhibits potent antitumor efficacy

• 徐霆 博士，康宁杰瑞CEO

LB030 / 22 - SHR-A1921, a novel TROP-2 ADC with an optimized design and well-balanced profile between efficacy and safety

• Linda Zhao，恒瑞医药

LB031 / 23 - SHR-A1811, a novel anti-HER2 ADC with superior bystander effect, optimal DAR and favorable safety profiles

• Linda Zhao，恒瑞医药

LB037 / 4 - Identification of imatinib-induced long noncoding RNAs involved in suppression of tumor growth mediated by bcr-abl oncogene

• 陈吉龙教授，福建农林大学

LB151 / 2 - Exploring the tumor microenvironment in a spatial context with SpaCET

• Beibei Ru, The University of Hong Kong, Hong Kong, China

LB154 / 5 - Circ0003039 interacts with calreticulin to inhibit the progression of hepatocellular carcinoma by suppressing wnt/beta-catenin signaling pathway

• Yue-Ning Wang, Yu-Feng Zhou, Ji Liu, Mei-Yin Zhang, Shuo-Cheng Wang, Shi-Juan Mai, Hui-Yun Wang. 中山大学肿瘤防治中心

LB210 / 3 - RenNano® mice: A heavy-chain-only antibody platform for the generation of nanobody therapeutics

• 沈月雷博士，百奥赛图

LB211 / 4 - Discovery of RenNano®-derived human heavy-chain-only antibodies that cross the blood-brain barrier

• 沈月雷博士，百奥赛图

LB212 / 5 - BCG022: A novel bispecific antibody-drug conjugate targeting HER3 and MET

• 杨毅博士，百奥赛图

LB213 / 6 - Identification of DM004, a first-in-class anti-5T4/MET bispecific antibody-drug conjugate

• 杨毅博士、林庆聪博士，百奥赛图

LB214 / 7 - A first-in-class bispecific antibody-drug conjugate (DM002) targeting HER3 and the juxtamembrane domain of MUC1

• 杨毅博士、林庆聪博士，百奥赛图

LB215 / 8 - A first-in-class anti-TROP2/EGFR bispecific antibody-drug conjugate, DM001, exhibits potent anti-tumor efficacy

• 杨毅博士、林庆聪博士，百奥赛图

LB216 / 9 - Discovery of BCG033, a novel anti-PTK7 x TROP2 bispecific antibody-drug conjugate with promising efficacy against triple-negative breast cancer

• 杨毅博士、林庆聪博士，百奥赛图

LB218 / 11 - Developing a bispecific anti-ROR1 antibody drug conjugate for hematological and solid tumor treatment

• Xiaobei Zhao，博锐生物

LB229 / 4 - Tinengotinib, a novel fibroblast growth factor receptor (FGFR) inhibitor, is potent against resistance mutations in FGFR1/2/3

• 强晓妍，药捷安康

LB262 / 14 - HSK38008: An oral AR-V7 degrader for metastatic castration-resistant prostate cancer

• 王菊博士，海思科医药

LB274 / 8 - Senescent cells develop PDK4-dependent hypercatabolism and form an acidic microenvironment to drive cancer resistance

• 孙宇研究员，中国科学院上海生科院

LB279 / 13 - Targeting microglial metabolic rewiring synergizes with immune checkpoint blockade therapy for glioblastoma

• 周圣涛教授，四川大学华西第二医院

LB289 / 2 - Longitudinal ctDNA levels and clinical outcomes of first-line (1L) tislelizumab (TIS) + chemotherapy (chemo) treatment for advanced non-small cell lung cancer (NSCLC) in the RATIONALE-304 and 307 studies

•陆舜教授，上海交通大学附属胸科医院

•王洁教授，中国医学科学院肿瘤医院

•百济神州

LB302 / 15 - Radiotherapy exposure and baseline gut microbiota predict clinical outcomes of fruquintinib plus sintilimab in microsatellite-stable metastatic colorectal cancer

• 金敏医生, 华中科技大学同济医学院附属协和医院

LB316 / 7 - A next-generation KRASG12C inhibitor ABSK071 demonstrated broad synergy with other therapeutic agents in KRASG12C mutated cancer models

• Haiyan Ying、陈椎博士，和誉生物

LB317 / 8 - Discovery and characterization of a next-generation FGFR inhibitor overcoming FGFR resistant mutations

• Haiyan Ying、徐耀昌博士，和誉生物

LB324 / 15 - BB3008, a potent and selective small molecular HPK1 inhibitor effective in multiple syngeneic tumor models

• 张兴民博士，伯汇生物

LB327 / 18 - Discovery and characterization of ABSK112, a next-generation and potential best-in-class EGFR Exon20 mutant inhibitor with superior selectivity and brain penetration ability

• Mei Ning、徐耀昌博士，和誉生物

LB328 / 19 - Discovery & characterization of a next-generation FGFR4 inhibitor overcoming resistant mutations

• Haiyan Ying、徐耀昌博士，和誉生物

LB329 / 20 - A potent and selective small molecule inhibitor of CSF-1R ABSK021 demonstrates strong efficacy in preclinical models of osteosarcoma

• Nannan Zhang、陈椎博士，和誉生物

LB330 / 21 - FHND5071: a selective RET inhibitor with unique pharmacokinetic profile

• 朱永强，创特医药

LB340 / 8 - Spur cell-delivered peptide antigen generates T cell immunity to eradicate mouse KRASG12D spontaneous lung cancer

• Ke Zen, 中国药科大学